SHIKARI® T-CAP Nab Assay™-Rituximab ELISA Kit
RIT-TCAP-NAb-RM
Target Capture Neutralizing Antibodies Immunoassay-Rituximab
Enzyme immunoassay to detect neutralizing antibodies to rituximab in serum and plasma samples
This kit has been developed for detecting ‘Free’ neutralizing antibodies to rituximab. The kit is composed of 4 different controls,
- Positive control: It contains netralizing antibody
- Negative control
- Cut-Off control: Contains certain amounted neutralizing antibody. Corresponse to lower limit of detection (LLOD)
- Non-Neutralizing Antibody Negative Control: Contains non-neutralizing antibodies binding to the drug
With these controls, the kit provides reliable results.
The Cut Off serum contains the LLOD amount and provides accurate true positive or negative results.
A non-neutralising antibody that binds to the drug without affecting the test results can be considered as a negative control.
The kit was also checked with various negative serum samples, including RF(+), CRP(+), ANA(+) sera. All these negative sera did not interfere with the test system. Please refer to the validation report.
We strictly recommend taking sample just before the next dose administration from the patient.
All SHIKARI® ELISA kits are produced under ISO 13485 quality system and have CE IVD mark.
For technical inquiry, please contact techsupport@matriksbiotek.com
| Required Volume (µl) | 10 |
| Total Time (min) | 140 |
| Sample | Serum, plasma |
| Sample Number | 96 |
| Detection Limit (ng/mL) | 50 |
| Spike Recovery (%) | - |
| Shelf Life (month) | 6 |
| Assay type | Qualitative |
| Species Reactivity | Human |
| Storage conditions | Store at +4°C. Please refer to protocols. |
| Shipping conditions | At room temperature |
| # | File | Action |
|---|---|---|
| Instructions For Use | Download | |
| SDS | Download | |
| Validation Report | Download |
Publications with this drug
| # | File | Action |
|---|---|---|
| Sinha, Aditi, et al. "Sequential rituximab therapy sustains remission of nephrotic syndrome but carries high risk of adverse effects." Nephrology Dialysis Transplantation 38.4 (2023): 939-949. | Visit Link | |
| Chen, Yewei, et al. "Population pharmacokinetics of rituximab in pediatric patients with frequent-relapsing or steroid-dependent nephrotic syndrome." Frontiers in Pharmacology 12 (2021): 725665. | Visit Link | |
| Liu, Shu, et al. "Rituximab exposure‐response in triweekly R‐CHOP treatment in DLBCL: A loading dose is recommended to improve clinical outcomes." Clinical and Translational Science 15.3 (2022): 680-690. | Visit Link | |
| Liu, Shu, et al. "Low initial trough concentration of rituximab is associated with unsatisfactory response of first-line R-CHOP treatment in patients with follicular lymphoma with grade 1/2." Acta Pharmacologica Sinica 42.4 (2021): 641-647. | Visit Link | |
| Bai, Yunfei, et al. "Anti-rituximab antibodies in patients with refractory autoimmune nodopathy with anti-neurofascin-155 antibody." Frontiers in Immunology 14 (2023): 1121705. | Visit Link | |
| Chen, Yewei, et al. "Using real-world data to inform dosing strategies of rituximab for pediatric patients with frequent-relapsing or steroid-dependent nephrotic syndrome: a prospective pharmacokinetic-pharmacodynamic study." Frontiers in Pharmacology 14 | Visit Link | |
| Abdullah, Iqbal Muaafi, et al. "The Diagnostic Value of Anti-rituximab Ab in Iraqi Patient with Chronic Lymphocytic Leukemia." International journal of health sciences 6.S6: 3005-3013. | Download |
